Asymmetry Capital Management


Our Team


Scott Kay, Founder & CIO

Scott Kay founded Asymmetry Capital Management in 2012. He began his career at Pfizer Inc., then joined Banc of America Securities, LLC, where he covered major pharmaceuticals. He was promoted to Senior Global Pharmaceuticals Analyst and was ranked "Best Up and Comer" by Institutional Investor. In 2003, he joined Andor Capital Management, a diversified long/short equity hedge fund, covering specialty and large-cap pharmaceuticals. When Andor closed, he became a Founding Partner and the Therapeutic Sector Head at Partner Fund Management (PFM), a San Francisco-based long/short equity hedge fund. After 7 years at PFM, he left in 2011 to launch Asymmetry.

Scott received his B.S. in Marketing, with a finance concentration, from the State University of New York at Oswego.

Scott Kay

Chris Zellner

Chris Zellner, Founder, COO & CCO

Chris Zellner, joined Asymmetry in 2012. Chris has over 25 years of financial services experience and has worked for The New York Stock Exchange (NYSE), Morgan Stanley, Lehman Brothers, Merrill Lynch and Bank of America Merrill Lynch. He has a diverse background in financial services, having worked in Prime Brokerage, Equity Derivatives, and Equity Capital Markets. Chris also created the NYSE's IPO listing business.

Chris received his B.S. and M.B.A. from the Stern School of Business at New York University.


Cindy Goldsmith, CFO

Cindy Goldsmith, CPA, joined Asymmetry in 2013. Previously, Cindy was the Manager of Hedge Fund Administration and Accounting Manager for Forward Management, and the Controller of Kensington Investment Group (acquired by Forward in 2009), where she was responsible for the accounting, taxes and administration of over 10 hedge funds. She was also a Manager at Kenneth Leventhal & Co, a certified public accounting firm.

Cindy received her B.S. in Accounting from the University of California, Berkeley.

Cindy Goldsmith, CFO

Zarak Khurshid

Zarak Khurshid, Analyst

Zarak Khurshid, joined Asymmetry in 2016. He covers all non-therapeutic healthcare sectors, which includes medical technology, devices, tools, diagnostics, labs, healthcare IT and services. Previously, Zarak worked as the Senior Vice President of Equity Research at Wedbush Securities PacGrowth Life Sciences, Caris & Company and as a Research Analyst at Pacific Growth Equities, LLC. He began his career in industry, working for Aurora Biosciences and Cytokinetics Inc.

Zarak received his B.A. in Economics and B.S. in Bioengineering from the University of California, San Diego.


Michael Manifesto, Analyst

Michael Manifesto, joined Asymmetry in 2014. He covers all healthcare sub-sectors. Michael worked as a Junior Analyst at Forward Management.

Michael received his B.S. in Business Administration, with a finance concentration, from California Polytechnic State University. Michael passed all three levels of the CFA exam on his first attempt.

Michael Manifesto

James Yin

James Z. Yin, Analyst

James Yin, Ph.D., joined Asymmetry in 2018. He covers major pharma, specialty pharma, generics and biotechnology. Previously, James worked as the Biotech Equity Research Associate at H.C. Wainwright. Before becoming an analyst, James worked as a Research Scientist at the University of Minnesota and as a Research Fellow at National Institutes of Health (NIH). His research on the atomic structure of the Rous Sarcoma Virus Intasome was published in the Journal Nature in February 2016. James received his undergraduate degree from Nankai University, his Ph.D. in Microbiology from the University of Texas at Austin, and his MBA from the University of Minnesota.